Whether psychedelic medicine costs you nothing or thousands of euros depends almost entirely on which country you are in — and on details as small as your age, how many treatments you have documented, and whether your psychiatrist knows which form to file. This is the map. It is checked against the leading sector sources — the Magnetar Access × Blossom reimbursement report (produced with Norrsken Mind), Blossom's continuously updated country reimbursement pages, and Psychedelic Alpha's access analyses — plus the primary regulators, and we re-verify it as decisions change. The eligibility decision itself always sits with a clinician; you can begin orienting yourself with our eligibility check.
TL;DR Esketamine (Spravato) is publicly reimbursed in most of continental Europe — Germany, the Netherlands, Poland, Switzerland, Belgium (since 2021), Italy, Ireland, Spain, Finland, Czechia, Portugal, Denmark (since 11/2025) — though nearly everywhere under strict treatment-resistance criteria. England is the big exception (NICE said no). Norway said no to Spravato but did something nobody else has: since August 2025 it publicly funds generic IV ketamine for treatment-resistant depression — a world first. Psychedelic-assisted therapy with psilocybin, LSD or MDMA is not routinely reimbursed anywhere yet; Switzerland's authorized program is self-pay, and Germany's psilocybin compassionate use program provides the drug free by law.
At a glance
| What it is | A country-by-country map of what public and private systems pay for esketamine, ketamine and psychedelic therapy in 2026 |
| Legal status | Spravato is licensed EU-wide; reimbursement is a separate national decision, so coverage and criteria differ by country |
| Who qualifies | Almost always documented treatment-resistant depression — a set number of failed antidepressants, sometimes plus augmentation, within age limits |
| Cost range | From fully covered (standard co-payments) where reimbursed, to several thousand euros self-pay where it is not |
| How to start | Assemble a written treatment history, then work with your psychiatrist to file under the pathway your country uses |
Country by country: what is reimbursed in 2026
| Country | What is reimbursed | Key criteria | Who decides |
|---|---|---|---|
| Germany | Spravato, incl. office-based practices since 10/2023 (own billing code) | TRD: ≥2 failed antidepressants in current moderate-to-severe episode | GKV coverage follows the label; psychiatrist prescribes (guide) |
| Netherlands | Spravato at ENC-NL specialized centers — insurers cover drug and treatment sessions | ≥2 antidepressants + ≥1 augmentation failed | Basic package since 09/2021; center confirms with insurer (guide) |
| Poland | Spravato fully funded, max 34 weeks | 18–75, ≥2 failed antidepressants in current episode | NFZ program B.147 center (guide) |
| Switzerland | Spravato at BAG-designated centers, max 10 months | 18–74, ≥2 antidepressants + 1 augmentation failed, CGI-S ≥5, insurer pre-approval | OKP Limitatio since 10/2025; insurer trust doctor (guide) |
| Belgium | Spravato since 06/2021, hospital-administered | Moderate-severe episode, ≥2 failed antidepressants; per-patient prior authorization | INAMI/RIZIV Chapter IV — insurer's advising physician approves each patient |
| Italy | Spravato as hospital medicine (Classe H) since 05/2022 | TRD: ≥2 failed antidepressants; AIFA monitoring registry | Regionally authorized psychiatric centers |
| Ireland | Spravato since 01/2022 | TRD, psychiatrist-initiated | HSE via specialist psychiatric services |
| Spain | Spravato as hospital medicine since 11/2022 | 18–74, ≥3 failed strategies incl. augmentation | Hospital psychiatry + pharmacy commission; regional variation (guide) |
| Finland | Spravato via Kela since 08/2023 — unique pharmacy-dispensing model | TRD on SSRI/SNRI, MADRS ≥31, ≥3 failed treatments incl. psychotherapy; psychiatrist's B-statement | Kela restricted reimbursement (codes 3062/1539); supervised administration, incl. outpatient settings |
| Czechia | Spravato since 02/2025; partial KAP coverage exists (Psyon) | Under 65, non-psychotic TRD, ≥2 optimized antidepressants failed | Insurers per SÚKL conditions; exceptional approval possible beyond criteria (guide) |
| Portugal | Spravato in hospital settings since 05/2025 | TRD with stricter national criteria (incl. prior therapy steps) | INFARMED financing decision; hospital administration |
| France | Spravato hospital-only; ketamine compassionate framework (03/2026) for suicidal crisis | Under 65, ≥2 antidepressants of 2 classes failed, ECT not an option | Hospital psychiatric department (guide) |
| Denmark | Spravato recommended 11/2025 (was already recommended for acute suicidal risk, admitted patients) | Moderate-severe TRD, ≥3 failed antidepressants in current episode | Medicinrådet recommendation; regional specialist delivery |
| Sweden | Formally possible but "strongly restrained" use advised | In practice after ~4+ failed alternatives; region-by-region funding | NT Council recommendation (rev. 11/2024); regions decide |
| Norway | Generic IV ketamine for TRD — world-first public funding (08/2025); Spravato rejected | TRD; treatment in public specialist service (hospitals and DPS centers), consent + registry follow-up | Beslutningsforum (Nye Metoder); decision to be re-evaluated by 2028 |
| UK — England & Wales | Nothing routine (NICE did not recommend esketamine); first NHS racemic-ketamine pilots exist | — | NICE TA854 / NHS trusts (guide) |
| UK — Scotland | Spravato, restricted | TRD, ≥2 failed antidepressants in current episode | SMC acceptance (2020), health board implementation |
| Austria | Not in the outpatient reimbursement code (EKO) | Inpatient covered via hospital financing; outpatient needs case-by-case chief-physician approval | Hospitals / sickness funds per case |
How to prepare a reimbursement case
Across every system above, one thing decides more cases than anything else: a documented treatment history. Before any referral, assemble — ideally with your GP or psychiatrist — a written record of every antidepressant and augmentation you have tried in the current episode: substance, dose, duration, outcome, side effects, plus any psychotherapy. "Adequate trial" means sufficient dose for sufficient duration; a week on a starting dose usually does not count. In pre-approval systems (Switzerland, Belgium, Finland, Czechia beyond criteria) this record is literally what the insurer's physician reads. If you do not yet have a formal diagnosis, a validated self-screener can help you prepare for the first appointment.
What to expect from the reimbursement process
Reimbursement rarely happens at a counter; it runs alongside your clinical assessment, and knowing the shape of it helps you avoid delays. In label-following systems (Germany, Scotland) the psychiatrist simply prescribes within the criteria, and the funding is built into how the treatment is billed. In pre-approval systems (Switzerland, Belgium, Finland, and Czechia beyond the standard criteria) an extra step comes first: the treating center submits a written request to your insurer, whose advising or trust physician reads your documented history against the criteria before the first dose is scheduled — a process that can add several weeks, so ask the center to start it early. In hospital-financed systems (France, Spain, Italy, Portugal) the drug is dispensed and administered within the hospital, and the hospital's own protocol or pharmacy commission is the gatekeeper as much as the national rule.
Two practical habits smooth all of these: let the center or hospital manage the insurer paperwork rather than doing it yourself, and ask up front how long the approval step typically takes in your region. Where a public route is closed, the honest fallback is self-pay at a vetted clinic — see our clinic-choice guide — or a clinical trial, which is free by definition.
Exceptional and individual-case pathways
Beyond the standard routes, most systems have a legal mechanism for covering treatment outside normal rules. These are real but demanding — success is case-by-case and usually requires a supportive specialist.
- Switzerland — Art. 71a–d KVV (individual-case reimbursement): insurers can cover medicines outside the approved list for serious disease with high expected benefit and no alternative. Realistic for esketamine outside the Limitatio (over 74, beyond 10 months); its use for authorized MDMA/LSD/psilocybin therapy is theoretically arguable but not documented in practice.
- Germany — §2 Abs. 1a SGB V: statutory route to individual coverage for life-threatening or gravely disabling illness with no standard alternative. No documented psychedelic case yet — a mechanism to know about, not to count on.
- Germany — psilocybin compassionate use: under the Härtefallprogramm (ZI Mannheim, OVID Berlin; TRD only), the law requires the drug to be provided free of charge; surrounding inpatient care is billed as normal hospital treatment.
- Czechia — exceptional insurer approval: documented practice of covering Spravato beyond standard criteria (e.g., patients over 65) when options are exhausted.
- Netherlands — outcomes-based coverage: Dutch insurers pioneered pay-for-performance contracts for esketamine, and a "promising care" pathway for oral esketamine is under formal review, with a basic-package decision expected around mid-2026.
- Norway — the off-label funding precedent: Beslutningsforum showed a public system can fund a cheap generic compound off-label, with registry follow-up, instead of waiting for a branded approval. Sector analysts expect other systems to study this model.
What is not reimbursed anywhere (yet)
Psychedelic-assisted therapy with psilocybin, MDMA or LSD has no routine public reimbursement in any European country as of mid-2026. Switzerland's limited-medical-use program (the only routine legal access) is essentially self-pay. Czechia's medical psilocybin framework became law in January 2026, but treatment had not started as of spring 2026 and no funding route is defined. Private ketamine and KAP clinics are self-pay everywhere, with the partial Czech exception above. If cost is the barrier: clinical trials are free by definition and often the strongest option where reimbursement is closed.
Frequently asked questions
My country reimburses Spravato — why is it still so hard to get?
Reimbursement is a funding decision, not a capacity decision. Uptake is limited by how few sites offer treatment (the observation requirement demands space and staff) and how many psychiatrists know the pathway. The Netherlands approved coverage in 2021, yet only a few dozen patients were treated in the first year against an eligible population estimated in the thousands.
Does private health insurance help?
Sometimes. Private policies can cover what public systems exclude (e.g., private Spravato in Germany via PKV, or faster access to specialists), but few explicitly cover ketamine or KAP. Always request written confirmation before starting.
I am over the age limit (65/74/75). Is that final?
Not always. Czechia has a documented exceptional-approval route, Switzerland has Art. 71a–d, Germany has §2 Abs. 1a SGB V — all case-by-case, all requiring a specialist willing to argue your case.
What does the drug itself do in a session, and can I drive after?
Esketamine is a supervised nasal spray followed by roughly two hours of observation with blood-pressure and heart-rate monitoring; ketamine is usually an infusion over about 40–60 minutes. Transient dissociation and a temporary rise in blood pressure are expected, and you should not drive for the rest of the day.
Who keeps this page honest?
We cross-check against the Magnetar/Blossom reimbursement report, Blossom's living country pages and Psychedelic Alpha's access coverage, then against primary regulators (G-BA, ZiN, NFZ, BAG, INAMI, AIFA, HSE, Kela, SÚKL, INFARMED, HAS, Medicinrådet, NT-rådet, Nye Metoder, NICE/SMC). Corrections are welcome — see the methodology page.
Sources
- Reimbursement Pathways for Psychedelic Therapies in Europe — Magnetar Access × Blossom, supported by Norrsken Mind (2025)
- Blossom — per-country medical access & reimbursement pages (updated 2026)
- Psychedelic Alpha — Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe's Real World (01/2026)
- Psychedelic Alpha — Norway Approves Public Funding for Generic Ketamine in TRD (08/2025)
- Nye Metoder — Ketamin (Beslutningsforum decision)
- Medicinrådet — esketamine recommendation, November 2025
- CBIP/BCFI — Spravato Chapter IV reimbursement, Belgium (06/2021)
- Kela — esketamine reimbursement, Finland (08/2023)
- Gazzetta Ufficiale — AIFA Determina 334/2022, Italy
- NCPE Ireland — esketamine HTA
- BAG — Spravato Limitatio and designated-center list (10/2025)
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with your insurer and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.